Parkinson Disease - Drug therapy
Research News and Information

Sunday, November 22, 2009

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

Nov 2009 OBJECTIVE: To investigate the incidence of and risk factors for cognitive impairment in a large, well-defined clinical trial cohort of patients with early Parkinson disease (PD). METHODS: The Mini-Mental State Examination (MMSE) was administered ... Read more...

[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review]

3 Oct 2009 The Cochrane analysis confirms some well-known facts: initial therapy with dopamine agonists (DA) delays the incidence of motor complications, but is associated with inferior motor control and a higher frequency of non-motor adverse events (AE) ... Read more...

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.

29 Sep 2009 Aiming to emulate the successful accelerated development of HIV/AIDS drugs, the Critical Path Institute (C-Path), in collaboration with the Engelberg Center for Health Care Reform at the Brookings Institution, has formed the Coalition Against Major ... Read more...

Latest indexed articles for 'Parkinson Disease - Drug therapy'

These are the very latest articles for this heading:

• Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Nov 2009
• [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review] 3 Oct 2009
• The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. 29 Sep 2009
• The delayed-start study design. 22 Sep 2009
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease. 22 Sep 2009
• Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease. 17 Sep 2009
• Drug-induced compulsive behaviors: exceptions to the rule. 30 Aug 2009
• [Management of Parkinson's disease in 2009] 24 Aug 2009
• A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. 22 Aug 2009
• An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease. 16 Aug 2009
• Methylation status and neurodegenerative markers in Parkinson disease. 11 Aug 2009
• Heat waves and the elderly. Drugs for Parkinson's disease. 2 Aug 2009
• Zonisamide: in Parkinson's disease. 30 Jul 2009
• Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. 30 Jul 2009
• Disparities in care: guilty until proven innocent. 30 Jul 2009
• Treatment disparities in Parkinson's disease. 30 Jul 2009
• Drug-induced dyskinesias. 30 Jul 2009
• Medical treatment of Parkinson disease. 30 Jul 2009
• Movement disorders. Preface. 30 Jul 2009
• Visualizing vesicular dopamine dynamics in Parkinson's disease. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Parkinson Disease'

Definition: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Descriptor UI: D010300

Alternative terms: Parkinson Disease; Idiopathic Parkinson's Disease; Lewy Body Parkinson Disease; Lewy Body Parkinson's Disease; Primary Parkinsonism; Parkinsonism, Primary; Parkinson Disease, Idiopathic; Parkinson's Disease; Parkinson's Disease, Idiopathic; Parkinson's Disease, Lewy Body; Idiopathic Parkinson Disease; Paralysis Agitans;

Related Mesh Headings: Lewy Bodies;

Allowable Qualifiers: blood; cerebrospinal fluid; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C10.228.140.079.862.500; C10.228.662.600.400; C10.574.812;

History Note: 1979(1963)

Technical Notes: drug ther: consider also ANTIPARKINSON AGENTS; /chem ind = PARKINSON DISEASE, SECONDARY/chem ind